# Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies

Source: https://onco.cc/trials/nct07446270/  
OnCo record `nct07446270` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cetuximab and nimotuzumab in pancreatic cancer, run by Chinese PLA General Hospital, not yet recruiting.

## Summary

Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies is a phase 2, interventional study registered as NCT07446270 by Chinese PLA General Hospital, with a registry enrolment figure of 90 participants, started 2026-03-03 and due to reach its primary completion in 2027-10-30. Interventions recorded: Colorectal cancer: Tunlametinib + cetuximab β; Pancreatic cancer: Tunlametinib + cetuximab β; Pancreatic cancer: Tunlametinib +Nimotuzumab. Conditions listed: Treatment for Advanced Colorectal Cancer; Treatment for Advanced Pancreatic Cancer. Primary outcome: ORR. Pancreatic eligibility wording from the registry: "Patients with histologically or pathologically confirmed advanced pancreatic cancer or advanced colorectal cancer who have failed standard therapy;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07446270
- Phase: 2
- Setting: A Cohort Clinical Study to Evaluate the Efficacy and Safety of Tunlametinib Combined With Anti-EGFR Monoclonal Antibody in Patients With RAS-mutated Advanced Gastrointestinal Malignancies
- Sponsor: Chinese PLA General Hospital
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07446270: https://clinicaltrials.gov/study/NCT07446270

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Nimotuzumab](https://onco.cc/drugs/nimotuzumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07446270.json